Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(40.0%)
Phase 1
6(40.0%)
N/A
2(13.3%)
Phase 3
1(6.7%)
15Total
Phase 2(6)
Phase 1(6)
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT03388996Unknown

Pelvic Microbiomes of Benign and Malignant Ovarian Diseases

Role: collaborator

NCT02831075Phase 1Unknown

A Clinical Study Using Adipose-derived Stem Cells for Diabetic Foot

Role: collaborator

NCT02834858Phase 1Unknown

Umbilical Cord Mesenchymal Stem Cells Infusion for Diabetes Related Vascular Complications

Role: collaborator

NCT02796079Phase 1Unknown

A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications

Role: collaborator

NCT02741414Not ApplicableUnknown

A Multi-center Study for Eradication of Refractory Helicobacter Pylori

Role: collaborator

NCT02689583Not ApplicableUnknown

A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection

Role: collaborator

NCT02374684Phase 1Completed

Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects

Role: collaborator

NCT02504437Phase 1Unknown

Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease

Role: lead

NCT02083731Phase 2Unknown

MSC for Treatment of CMV Infection

Role: collaborator

NCT02291770Phase 3Unknown

Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells

Role: collaborator

NCT02241018Phase 2Unknown

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Role: collaborator

NCT02240992Phase 2Unknown

MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment

Role: collaborator

NCT02241031Phase 2Unknown

Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia

Role: collaborator

NCT02083718Phase 2Unknown

Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function

Role: collaborator

NCT01925352Phase 1Unknown

Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease

Role: collaborator

NCT00717951Phase 2Unknown

A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Role: lead

All 16 trials loaded